EUROBIO-SCIENTIFIC DISCLOSURECurrent Reports (8-K / ad hoc)

Eurobio Scientific: First half of 2026, Continuation of the strategic transformation

TEPA FCPI PRESS RELEASE Page 1 / 2 FIRST HALF OF 2026, CONTINUATION OF THE STRATEGIC TRANSFORMATION • First-half revenue up 5% to €84.5 million • Continuation of the Group’s strategy: o Proprietary products: 37% of revenue o International expansion: 47% of revenue generated outside France Paris, July 28, 2026 – 5:45 pm Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro medical diagnostics and life sciences, today reports its half-year revenue as of June 30, 2026. 5% revenue growth As of June 30, 2026, Eurobio Scientific reported revenue of €84.5 million, compared to €80.7 million as of June 30, 2025, representing an increase of approximately 5%. On a comparable pro forma basis— that is, excluding the impact of changes in scope resulting from acquisitions—revenue remained stable. The impact of changes in scope primarily relates to the integration of the acquisition of the Life Sciences unit of Voden Medical Instruments Spa, which reported revenue of €3.8 million. in €m June 30, 2026 June 30, 2025 Change Revenue 84.5 80.7 + 4.7% unaudited The share of proprietary products continues to grow Revenue from proprietary products totaled €31.3 million as of June 30, 2026, up 10% compared to the first half of 2025. Excluding the impact of changes in scope, growth stood at 7%. Proprietary products account for approximately 37% of the Group’s revenue, driven in particular by GenDx’s contribution in the field of transplantation and the product lines in infectious diseases and quality control. Revenue from distributed products remained broadly stable Revenue from distributed products totaled €53.2 million as of June 30, 2026, up 2% compared to the first half of 2025. Excluding changes in scope, revenue declined by 5%, primarily due to the end of tenders for One Lambda products. Seegene Distribution Agreement Eurobio Scientific and the South Korean company Seegene have been partners since 2011 under a distribution agreement that generated approximately €48 million in revenue for fiscal year 2025. Seegene has indicated its desire to enter the French market directly upon the expiration and in accordance with the terms of the distribution agreement, which ends on December 31, 2026, TEPA FCPI Page 2 / 2 The distribution agreement does indeed provide f